C. Hopkinson Craig's Insider Trades & SAST Disclosures
C. Hopkinson Craig's most recent trade in Alkermes plc was a trade of 6,866 Ordinary Shares done . Disclosure was reported to the exchange on Feb. 26, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern C. Hopkinson Craig.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 80,789 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 20,598 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 3,049 | 77,740 (0%) | 0% | 34.8 | 106,090 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 12,279 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 12,279 | 75,100 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 15,379 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 77,337 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 5,452 | 69,648 (0%) | 0% | 35.3 | 192,565 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,414 | 73,923 (0%) | 0% | 35.3 | 120,582 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 63,991 | 63,991 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 30,692 | 30,692 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 66,771 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 8,897 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 3,950 | 62,821 (0%) | 0% | 35.9 | 141,805 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.69 per share. | 12 Feb 2025 | 171,813 | 90,983 (0%) | 0% | 32.7 | 5,616,808 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 12 Feb 2025 | 111,630 | 262,796 (0%) | 0% | 19.3 | 2,158,924 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 111,630 | 50,104 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 108,833 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.02 per share. | 12 Feb 2025 | 108,833 | 57,875 (0%) | 0% | 36.0 | 3,920,001 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.93 per share. | 12 Feb 2025 | 108,833 | 166,708 (0%) | 0% | 31.9 | 3,475,038 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 87,566 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 12 Feb 2025 | 87,566 | 151,166 (0%) | 0% | 20.0 | 1,753,947 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 12 Feb 2025 | 35,586 | 166,708 (0%) | 0% | 34.0 | 1,210,696 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 12 Feb 2025 | 35,586 | 202,294 (0%) | 0% | 24.6 | 875,060 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 35,586 | 71,172 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 12 Feb 2025 | 33,108 | 57,875 (0%) | 0% | 33.3 | 1,101,470 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,393 | 78,683 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 15,083 | 63,600 (0%) | 0% | 31.4 | 473,455 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.05 per share. | 30 Jan 2025 | 100,918 | 44,290 (0%) | 0% | 32.0 | 3,234,382 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 30 Jan 2025 | 29,156 | 76,732 (0%) | 0% | 20.0 | 583,995 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 29,156 | 87,566 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 30 Jan 2025 | 26,589 | 103,321 (0%) | 0% | 19.3 | 514,231 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 26,589 | 161,734 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 30 Jan 2025 | 23,542 | 126,863 (0%) | 0% | 24.6 | 578,898 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 23,542 | 106,758 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.82 per share. | 30 Jan 2025 | 18,345 | 145,208 (0%) | 0% | 26.8 | 492,013 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 18,345 | 92,271 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 09 Dec 2024 | 61,151 | 47,576 (0%) | 0% | 32.1 | 1,961,406 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 09 Dec 2024 | 12,452 | 72,182 (0%) | 0% | 20.0 | 249,414 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,452 | 116,722 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,411 | 110,616 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.82 per share. | 09 Dec 2024 | 12,411 | 108,727 (0%) | 0% | 26.8 | 332,863 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,090 | 188,323 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 09 Dec 2024 | 12,090 | 84,272 (0%) | 0% | 19.3 | 233,821 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,044 | 130,300 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 09 Dec 2024 | 12,044 | 96,316 (0%) | 0% | 24.6 | 296,162 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.50 per share. | 05 Dec 2024 | 9,221 | 59,730 (0%) | 0% | 31.5 | 290,462 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.77 per share. | 04 Dec 2024 | 14,349 | 68,951 (0%) | 0% | 30.8 | 441,550 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.08 per share. | 11 Nov 2024 | 58,996 | 83,300 (0%) | 0% | 30.1 | 1,774,576 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 11 Nov 2024 | 43,058 | 142,296 (0%) | 0% | 20.0 | 862,452 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 43,058 | 129,174 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.53 per share. | 06 Nov 2024 | 10,471 | 99,238 (0%) | 0% | 29.5 | 309,169 | Ordinary Shares |
| Alkermes plc | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 111,186 | 111,186 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 27,464 | 27,464 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 23,068 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 113,123 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 3,414 | 109,709 (0%) | 0% | 29.6 | 100,952 | Ordinary Shares |
| Alkermes plc | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 12,278 | 12,279 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 12,278 | 110,886 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 5,452 | 105,434 (0%) | 0% | 28.9 | 157,617 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 10,297 | 103,180 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 10,297 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 96,834 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 17,793 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | C. Craig Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 4,572 | 98,608 (0%) | 0% | 30.4 | 138,943 | Ordinary Shares |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 3,951 | 92,883 (0%) | 0% | 32.2 | 127,143 | Ordinary Shares |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 46,658 | 103,217 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 15,280 | 87,937 (0%) | 0% | 26.8 | 409,046 | Ordinary Shares |
| Alkermes plc | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 3,929 | 200,413 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 3,376 | 172,232 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,790 | 142,344 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,412 | 123,027 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,133 | 108,833 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,599 | 81,599 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,089 | 55,589 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 603 | 30,757 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 523 | 26,690 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 481 | 24,557 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | C. Craig Hopkinson | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 201 | 10,297 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 120,615 | 120,615 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 30,154 | 30,154 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 12,038 | 61,904 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 12,038 | 24,076 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.77 per share. | 22 Feb 2023 | 5,345 | 56,559 (0%) | 0% | 27.8 | 148,431 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2023 | 22,195 | 52,570 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 10,095 | 34,155 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 10,095 | 10,096 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 8,722 | 26,716 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 8,722 | 26,167 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 6,875 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 6,875 | 52,919 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.07 per share. | 18 Feb 2023 | 6,526 | 46,044 (0%) | 0% | 28.1 | 183,185 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.07 per share. | 18 Feb 2023 | 3,780 | 30,375 (0%) | 0% | 28.1 | 106,105 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.77 per share. | 18 Feb 2023 | 3,053 | 49,866 (0%) | 0% | 27.8 | 84,782 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.07 per share. | 18 Feb 2023 | 2,656 | 24,060 (0%) | 0% | 28.1 | 74,554 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.76 per share. | 23 Feb 2022 | 11,983 | 17,994 (0%) | 0% | 24.8 | 296,650 | Ordinary Shares |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 139,554 | 139,554 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 34,889 | 34,889 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 12,037 | 33,516 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 12,037 | 36,114 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 10,096 | 19,592 (0%) | 0% | - | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges